News - OxyDial Inc

Nov 26 2025

Agios’s Oral Therapy Mitapivat Meets Primary Goal in Phase 3 Sickle Cell Disease Trial

Agios Pharmaceuticals has announced positive top-line results from its Phase 3 RISE UP trial, demonstrating that its oral therapy, mitapivat, significantly increased hemoglobin levels in patients with sickle cell disease …

OxyDial

Nov 20 2025

Disc Medicine’s Therapy Enters Clinical Trial in SCD, Offering a Novel Approach to Iron Overload

Disc Medicine has initiated a Phase 1b clinical trial for DISC-3405, an investigational therapy designed to address iron overload in patients with sickle cell disease (SCD). The trial will evaluate …

OxyDial

Oct 29 2025

Counting Down to PACT Capital Conference 2025 – Join Us in Philadelphia This October!

We’re now just days away from the Mid-Atlantic Capital Conference, and the excitement at OxyDial continues to build as we prepare to take the stage on October 30th at the …

OxyDial

Oct 17 2025

OxyDial Shares Warm Thanks To the SAMB Community and Sponsors

OxyDial recently had the privilege to attend the Society for the Advancement of Patient Blood Management (SABM) Annual Meeting in Minneapolis, where we were warmly welcomed as a new member …

OxyDial

Oct 10 2025

We’re excited to share that OxyDial has been selected to present at the Mid-Atlantic Capital Conference 2025!

We’ll be taking the stage in the Healthcare Track, sharing our vision for precision hemoglobin and blood analysis with investors, industry leaders, and innovators shaping the future of healthcare. This …

OxyDial

Oct 3 2025

Honored to join the 27th Annual Walter E. Brandon 5K Walk / Fun Run

Over the weekend, OxyDial stood beside an incredible community – people living with sickle cell disease, caregivers, advocates, and partners – united under one purpose: to raise awareness, share real …

OxyDial

Sep 26 2025

OxyDial At the Society for the Advancement of Patient Blood Management, Inc. (SABM) Annual Meeting

Last week, we had the privilege of attending the Society for the Advancement of Patient Blood Management, Inc. (SABM) Annual Meeting. We were deeply inspired by the presentations from leading …

OxyDial

Sep 18 2025

Fulcrum Therapeutics Showcases Promising Posiradir Data, Bolstering Confidence in a New Sickle Cell Disease Paradigm

Fulcrum Therapeutics presented compelling Phase 1B data for its lead candidate, Posiradir, at the H.C. Wainwright Conference, underscoring its potential as a novel oral treatment for sickle cell disease (SCD). …

OxyDial

Sep 10 2025

Sanofi’s Wayrilz Secures FDA Approval, Pioneering a New BTK Era in Immune Thrombocytopenia

Sanofi has achieved a significant milestone with the FDA approval of Wayrilz (rilzabrutinib) for immune thrombocytopenia (ITP), marking it as the first Bruton’s tyrosine kinase (BTK) inhibitor approved for this …